vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVTFree Report) in a report issued on Tuesday morning. The firm issued a sell rating on the biotechnology company’s stock.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT opened at $8.43 on Tuesday. The firm has a market cap of $22.00 million, a PE ratio of -0.78 and a beta of 0.27. vTv Therapeutics has a 52 week low of $7.38 and a 52 week high of $39.60. The firm’s fifty day moving average is $9.83 and its 200-day moving average is $16.95.

vTv Therapeutics (NASDAQ:VTVTGet Free Report) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($3.20) EPS for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VTVT. Pathstone Family Office LLC acquired a new stake in shares of vTv Therapeutics during the third quarter worth $116,000. Prudential Financial Inc. acquired a new stake in vTv Therapeutics during the 2nd quarter worth about $30,000. State Street Corp raised its position in shares of vTv Therapeutics by 268.7% in the 2nd quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after acquiring an additional 150,228 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of vTv Therapeutics by 12.0% in the 2nd quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 14,845 shares during the period. Institutional investors own 3.36% of the company’s stock.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

Read More

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.